Our approach in Fibrosis
- Right Targets. Right Cells. Right Place.
- Specifically target pathogenic myofibroblasts to break the fibrotic cycle and enable active fibrosis reversal, not just slowing disease progression.
Our approach in therapeutic modality design
- Staged modality expansion from target inhibition to selective cell depletion:
- mAb/nAb → BiME™ → in vivo CAR
Our approach in AI-Powered Biomarker Development
Please contact us for more information